Maureen Achebe, MD, MPH, Shares Extended Durable Data on Voxelotor for SCD


Maureen Achebe goes into detail about the open label extension of the HOPE trial that evaluated to use of Voxelotor in patients with sickle cell disease and anemia.

The latest results from HOPE trial open label extension showed that after 144 weeks, the majority of patients with sickle cell disease (SCD) taking voxelotor (Oxbryta) continued to see the positive results previously revealed in the trial, without any unexpected adverse events.

Maureen Achebe, MD, MPH, Assistant Professor of Medicine, Hematology, Brigham and Women's Hospital, presented the interim analysis of the open label extension of the HOPE trial at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

According to Achebe, there were no severe adverse events but there were some.

"The adverse events were pain crisis, which we expect in patients who have sickle cell disease, arthralgias, some abdominal upset, and minor adverse events that were reversible," she said.

The open label extension followed the HOPE trial. HOPE was a randomized control trial that examined the use of voxelotor, a molecule that increases hemoglobin's affinity for oxygen, currently indicated for patients with sickle cell disease and anemia.

"The HOPE trial was, I think, a remarkable study and that we were able to enroll patients onto the study in record time with positive results," Achebe said. "And the open label extension shows us that the improvements in hemoglobin that were achieved in HOPE are durable, and that the side effect profile, even over a longer period of time, has not expanded to include side effects that we didn't see on trial."

Watch the first segment of Dr. Achebe's interview with HCPLive®.

Related Videos
Elna Saah, MD: Unraveling the Current Landscape of Sickle Cell Disease | Image Credit: Twitter
Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes | Image Credit: Scott Graham/Unsplash
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
© 2024 MJH Life Sciences

All rights reserved.